Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India.
Diabetes Metab Syndr
; 15(4): 102196, 2021.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1293738
ABSTRACT
AIMS:
Diabetes Mellitus predisposes patients to invasive fungal infections. There has been a recent surge of Mucormycosis with COVID 19 infection particularly in patients with diabetes. This study aims to study the clinical spectrum of CAM (COVID -associated Mucormycosis) with diabetes and subsequent outcomes. MATERIAL ANDMETHODS:
This was a descriptive study conducted at a single COVID Care Centre in India in patients with COVID Associated Mucormycosis from April 12, 2021 to May 31, 2021.RESULTS:
Among 953 hospitalized patients with COVID 19 infection, 32 patients had CAM with an incidence of 3.36%. In patients with CAM, 87.5% had Diabetes Mellitus as the most common co-morbidity. The majority of the patients had poor glycemic control with a mean HbA1c of 9.06%. Out of the total study population, 93% had prior exposure to high dose corticosteroids. During the study period, 12.5% patients of CAM did not survive.CONCLUSION:
Mucormycosis is an angioinvasive fungal infection with high mortality. The disease has surged in COVID 19 pandemic due to uncontrolled diabetes and improper corticosteroid use.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Diabetes Mellitus
/
SARS-CoV-2
/
COVID-19
/
Hospitalización
/
Mucormicosis
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Tópicos:
Covid persistente
Límite:
Femenino
/
Humanos
/
Masculino
/
Middle aged
País/Región como asunto:
Asia
Idioma:
Inglés
Revista:
Diabetes Metab Syndr
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS